AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...
FiercePharma3d
AstraZeneca's Fasenra plays catch-up with GSK's Nucala, gaining FDA nod for rare autoimmune disease
Since GSK’s Nucala and AstraZeneca’s Fasenra were approved two years apart to treat patients with severe asthma, the IL-5 ...
GlobalData on MSN2d
AstraZeneca’s Fasenra to challenge GSK’s Nucala in rare vasculitis after FDA nod
Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...
Zacks.com on MSN3d
AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease
AstraZeneca AZN announced that the FDA has approved its marketed asthma drug, Fasenra (benralizumab) for a new indication.
Yahoo Finance2d
AstraZeneca’s Fasenra meets primary endpoint in Phase III rare vasculitis trial
AstraZeneca’s Fasenra (benralizumab ... It initially presents as adult-onset asthma before progressing to multi-organ failure ...
Daily2d
FDA approves Benralizumab for eosinophilic granulomatosis with polyangiitis
AstraZeneca's Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic ...
Managed Healthcare Executive3d
FDA Approves Fasenra for Treatment of Eosinophilic Granulomatosis with Polyangiitis
More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.
US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices
On Friday, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers ...
London South East3d
AstraZeneca Fasenra treatment for EGPA approved in the US
Ruud Dobber, executive vice president of AstraZeneca's BioPharmaceuticals business unit, said: "Fasenra is already well established for the treatment of severe eosinophilic asthma, and with this ...
EuropaWire3d
FDA Approves AstraZeneca’s Fasenra for Eosinophilic Granulomatosis with Polyangiitis, Offering New Hope for Patients
AstraZeneca's Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with ...
MedPage Today12d
Twice-Yearly Biologic Cuts Severe Asthma Exacerbation Rate in Half
The phase IIIA trials randomized 792 patients ages 12 and older with severe asthma in a 2:1 ratio to depemokimab (100 mg ...
MedPage Today15d
Asthma Biologics OK During Pregnancy if Patient Agrees, Consensus Statement Says
Biologic drugs for asthma may be initiated or continued while conceiving or during pregnancy or breastfeeding following ...